Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Qiu-zhong Pan"'
Autor:
Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT03950154
Externí odkaz:
https://doaj.org/article/2291e0ba14894e5bb2ec30a9d2eba1bf
Autor:
Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/ba71c9b1b1fe4145b05022e7b1aa3434
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 74-85 (2022)
Abstract Objective This study was designed to establish and validate promising and reliable nomograms for predicting the survival of angiosarcoma (AS) patients. Methods The Surveillance, Epidemiology, and End Results database was queried to collect t
Externí odkaz:
https://doaj.org/article/87971bfe7dac42d9b591b3677735898f
Autor:
Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-16 (2020)
Abstract Background Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms involved in RCC is
Externí odkaz:
https://doaj.org/article/adf556a0a1964c06ad93d70cfbcfc683
Autor:
Zi-Qi Zhou, Jing-Jing Zhao, Qiu-Zhong Pan, Chang-Long Chen, Yuan Liu, Yan Tang, Qian Zhu, De-Sheng Weng, Jian-Chuan Xia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical analysis of the patien
Externí odkaz:
https://doaj.org/article/51893445bec94660bcf1be1b3518e5b2
Autor:
Dan-dan Wang, Yi-bing Chen, Jing-jing Zhao, Xiao-fei Zhang, Guang-chao Zhu, De-sheng Weng, Ke Pan, Lin Lv, Qiu-zhong Pan, Shan-shan Jiang, Lei-lei Wang, Jian-chuan Xia
Publikováno v:
Cancer Communications, Vol 39, Iss 1, Pp 1-14 (2019)
Abstract Background In our previous study, we identified a candidate tumor suppressor gene, testin LIM domain protein (TES), in primary gastric cancer (GC). TES contains three LIM domains, which are specific interacting regions for the cell adhesion
Externí odkaz:
https://doaj.org/article/701d3243ac8140028bd2edc2ef35fc24
Autor:
Ze-Xian Liu, Wei Xiao, Jing-Jing Zhao, Qiu-Zhong Pan, De-Sheng Weng, Yi Que, Xiao-Long Zhang, Xi-Zhi Wen, Bu-Shu Xu, Dong-Chun Hong, Tian-Hui Guo, Lu-Jun Shen, Wei-Jun Fan, Huo-Ying Chen, Hai-Rong Xu, Peng-Hui Zhou, Yi-Zhuo Zhang, Xiao-Hui Niu, Xing Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background The advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the
Externí odkaz:
https://doaj.org/article/e988ecebac5347968984760e03511f4d
Autor:
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 3, Pp n/a-n/a (2021)
Abstract Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib
Externí odkaz:
https://doaj.org/article/207802f67c564291ab3647874de5462f
Autor:
Qiu-Zhong Pan, Jing-Jing Zhao, Chao-Pin Yang, Yu-Qing Zhou, Jun-Zhong Lin, Yan Tang, Jia-Mei Gu, Qi-Jing Wang, Yong-Qiang Li, Jia He, Shi-Ping Chen, Meng-Jia Song, Yue Huang, Jie-Ying Yang, De-Sheng Weng, Jian-Chuan Xia
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Adjuvant chemotherapy after surgery is the standard treatment modality for stage III and part of stage II or stage IV colorectal cancer (CRC) patients. However, the 5-year overall survival (OS) rate remains unsatisfactory. Thus, developing combinatio
Externí odkaz:
https://doaj.org/article/808971fc44914db7b98dbeeccb0665b0
Autor:
Qiu‐Zhong Pan, Jia‐Mei Gu, Jing‐Jing Zhao, Yan Tang, Qi‐Jing Wang, Qian Zhu, Meng‐Jia Song, Yong‐Qiang Li, Jia He, Shi‐Ping Chen, De‐Sheng Weng, Jian‐Chuan Xia
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 2, Pp n/a-n/a (2020)
Abstract Objectives Fluoropyrimidine‐based chemotherapy regimens are the current first‐line treatment for metastatic colorectal cancer (mCRC); however, the outcome is often unsatisfactory. The present study aimed to determine the effect of combin
Externí odkaz:
https://doaj.org/article/8033bc0eb1bd4584867b6ce545809720